Cyclin dependent kinases
as targets for cancer therapy.
Seliciclib (CYC202 or r-roscovitine) is novel cell cycle drug belonging to the Cyclin Dependent Kinase
(CDK) inhibitor class.
CYC202 (R-roscovitine) is a novel cell cycle drug belonging to the Cyclin Dependent Kinase
(CDK) inhibitor class (US Patent 6,316,456).
CYC202, a Cyclin Dependent Kinase
inhibitor in Phase II clinical trials for Non-Small Cell Lung cancer and in B cell hematological malignancies and CYC682 an orally available nucleoside analog in Phase Ib trials for cancer.
Most advanced is CYC202, a Cyclin Dependent Kinase
(CDK) inhibitor, currently in Phase II trials for cancer.
It is claimed to be a selective cyclin dependent kinase
inhibitor that will decrease the progress of cancer by inhibiting two proteins called cyclin dependent kinase
4 and 6 (CDK4/6).
Paracelsian's team of scientists discovered that there is a consistent relationship between cyclin dependent kinase
concentrations and cell growth and proliferation.